Skip to main content
Update Location

My Location

Update your location to show providers, locations, and services closest to you.

Enter a zip code
Select a campus/region


  • Status
    Accepting Candidates
  • Age
    12 Years - 35 Years
  • Sexes
  • Healthy Volunteers


A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.


This study has a total sample size of 78 participants. Of that 78, 52 participants will receive active treatment, and a total of 26 participants will receive placebo. Participants will receive 12 months of active treatment with abrocitinib, ritlecitinib, or placebo with up to 12 months of additional follow-up. During the study, participants will undergo frequent assessments of their insulin production, immunologic status, overall health and well-being and diabetes care.


Full study title TN31 JAK Inhibitors to Preserve C-Peptide Production in New Onset T1D (JAKPOT T1D) Study
Protocol number OCR44273 ID NCT05743244
Phase Phase 2


Inclusion Criteria:

  1. Provide informed consent or assent as appropriate and, if < 18 years of age have a parent or legal guardian provide informed consent

  2. Age 12-35 years (both inclusive) at the time of signing informed consent and assent

  3. Diagnosis of T1D within 100 days of the baseline visit (V0. .

  4. Positive for at least one islet cell autoantibody; Glutamate decarboxylase (GAD)65A, mIAA (if obtained within 10 days of the onset of insulin therapy), IA-2A, ICA, or ZnT8A

  5. Stimulated C-peptide of ≥0. 2 pmol/mL measured during mixed-meal tolerance test (MMTT) conducted at least 21 days from diagnosis of diabetes

  6. HbA1c ≤ 10 %

  7. Body weight ≥ 35kg at screening

  8. Willing to comply with intensive diabetes management and wear a Continuous Glucose Monitoring Device (CGM)

  9. Participants who are Cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV) seronegative at screening must be CMV and/or EBV Polymerase chain reaction (PCR) negative within 30 days of randomization and may not have had signs or symptoms of a CMV and/or EBV-compatible illness lasting longer than 7 days within 30 days of the baseline visit (V0).

  10. Be up to date on recommended immunizations; participants are required to receive

killed influenza vaccination at least 2 weeks prior to the baseline visit (V0) when

vaccine for the current or upcoming flu season is available. Enrollment must be

delayed at least 4 weeks from administration of a killed vaccine other than influenza

and 6 weeks from a live vaccination. Vaccinations should not be given while on study

drug and be postponed at least 3 months after the last dose of study drug.

  1. Participants are required to be fully vaccinated including eligible boosters and

should receive an authorized non-live COVID-19 vaccination series or COVID-19 vaccine

at least 2 weeks prior to the baseline visit (V0).

  1. If participant is female with reproductive potential, she must have a negative

pregnancy test at screening and be willing to avoid pregnancy using a highly-effective

contraceptive method for the duration of the study

  1. Males of reproductive age must use a highly-effective contraceptive method during the

treatment phase and for 3 months following last dose of study drug

Exclusion Criteria:

  1. Current or ongoing use of non-insulin pharmaceuticals or medication that affect glycemic control or glucose homeostasis within 7 days prior to screening or any prohibited concomitant medication listed in section 4.8

  2. Untreated hypothyroidism or active Graves' disease

  3. Concurrent treatment with other immunosuppressive agents (including biologics or steroids), other than inhaled or topical glucocorticoids

  4. Active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 1 month prior to Day 0 or superficial skin infection within 1 week prior to Day 0

  5. Active acute or chronic infection requiring treatment with intravenous therapy (IV) within a minimum 1 month prior to Day 0 a. Specific cases should be reviewed by Infectious Disease Committee prior to enrollment

  6. Have active signs or symptoms of acute infection at the time of the baseline visit (V0).

  7. Significant trauma or major surgery within 1 month of signing informed consent.

  8. Considered in imminent need for surgery or with elective surgery scheduled to occur during the study

  9. History of disseminated herpes zoster or disseminated herpes simplex or a recurrent (more than one episode of) localized, dermatomal herpes zoster

  10. Have evidence of prior or current tuberculosis infection as assessed by Purified

Protein Derivative (PPD), interferon gamma release assay (IGRA) or by history

  1. Have evidence of current or past HIV or Hepatitis B infection

  2. Have evidence of active Hepatitis C infection

  3. Have current, confirmed COVID-19 infection

  4. Current or history of Deep vein thrombosis (DVT), Pulmonary embolism (PE), or other

thromboembolic events or history of inherited coagulopathies

  1. First degree relative with a history of unprovoked venous thromboembolism (i.e.

without known underlying cause such as trauma, surgery, immobilization, prolonged

travel, pregnancy, hormone use, or plaster cast), which suggests that a participant

may be at increased risk of inherited coagulation disorder

  1. Any present malignancies or history of malignancy, other than a successfully treated

nonmelanoma skin cancer

  1. History of any lymphoproliferative disorder such as EBV-related lymphoproliferative

disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive

of current lymphatic or lymphoid disease

  1. Known or suspected polymorphism in the Cytochrome P450 2C19 (CYP2C19 gene, resulting

in classification as a poor CYP2C19 metabolizer).

  1. Have renal impairment (eGFR< 60 mL/min)

  2. Currently on anti-platelet therapies, excluding low dose aspirin

  3. One or more screening laboratory values as stated

  4. Neutrophils < 1,500 /μL

  5. Lymphocytes < 800 /μL

  6. Platelets < 150,000 / μL

  7. Hemoglobin < 6. 2 mmol/L (10. 0 g/dL)

  8. Potassium > 5. 5 mmol/L or 150mmol/L or < 130mmol/L

  9. AST or ALT ≥ 2. 5 times the upper limit of normal

  10. Bilirubin ≥ 1. 5 times upper limit of normal unless diagnosed with Gilbert's syndrome

  11. LDL >160 mg/dL

  12. Vaccination with a live virus within the last 6 weeks and killed vaccine within 4

weeks (except 2 weeks for flu vaccine and COVID vaccine)

  1. Be currently pregnant or lactating or anticipate becoming pregnant during the study

  2. Male participants able to father children and female participants of childbearing

potential who are unwilling or unable to use 2 effective methods (at least 1 highly

effective method) of contraception, including abstinence, as outlined in this protocol

for the duration of the study and for at least 3 months after the last dose of

investigational product

  1. Be currently participating in another T1D treatment study

  2. Have hearing loss with progression over the previous 5 years, or sudden hearing loss,

or middle or inner ear disease such as otitis media, cholesteatoma, Meniere's disease,

labyrinthitis, or other auditory condition that is considered acute, fluctuating, or


  1. Acute coronary syndrome (e.g., myocardial infarction, unstable angina pectoris) and

any history of cerebrovascular disease within 24 weeks before screening; Heart failure

NYHA (New York Heart Association) III, NYHA IV

  1. ANY of the following conditions at screening:

a. Screening 12-lead electrocardiogram (ECG) that demonstrates: i. Clinically

significant abnormalities requiring treatment (eg, acute myocardial infarction,

serious tachy* or brady-arrhythmias) or indicating serious underlying heart disease

(eg, cardiomyopathy, Wolff-Parkinson* White syndrome); ii. Confirmed QT corrected

using Fridericia's correction factor (QTcF) prolongation (>450 milliseconds).

b. Long QT Syndrome, a family history of Long QT Syndrome, or a history of Torsades de

Pointes (TdP).

  1. History of chronic alcohol abuse or intravenous drug abuse or other illicit drug abuse

within 2 years prior to screening

  1. Current or past use of tobacco or nicotine containing products more than the

equivalent of 5 cigarettes per day

  1. Participant is the investigator or any sub-investigator, research assistant,

pharmacist, study coordinator, other staff or relative thereof directly involved in

the conduct of the trial

  1. Have any complicating medical issues or abnormal clinical laboratory results that may

interfere with study conduct, or cause increased risk

  1. Any condition that in the investigator's opinion may adversely affect study

participation or may compromise the study results

Lead researchers

Participate in a study

Here are some general steps to consider when participating in a research study:

  1. Step

    Contact the research team

    Call or email the research team listed within the specific clinical trial or study to let them know that you're interested. A member of the research team, such as the researcher or study coordinator, will be available to tell you more about the study and to answer any questions or concerns you may have.

    Primary contact

    Laura Jacobsen
    Michael Haller
  2. Step

    Get screened to confirm eligibility

    You may be asked to take part in prescreening to make sure you are eligible for a study. The prescreening process ensures it is safe for you to participate. During the prescreening process, you will be asked some questions and you may also be asked to schedule tests or procedures to confirm your eligibility.

  3. Step

    Provide your consent to participate

    If you are eligible and want to join the clinical trial or study, a member of the research team will ask for your consent to participate. To give consent, you will be asked to read and sign a consent form for the study. This consent form explains the study's purpose, procedures, risks, benefits and provides other important information, such as the study team's contact information.

  4. Step


    If you decide to participate in a clinical trial or study, the research team will keep you informed of the study requirements and what you will need to do to throughout the study. For some trials or studies, your health care provider may work with the research team to ensure there are no conflicts with other medications or treatments.